Previous 10 | Next 10 |
Amryt Pharma press release ( NASDAQ: AMYT ): Q3 GAAP EPS of -$0.06. Revenue of $61.1M (+8.1% Y/Y). FY 2022 revenue guidance of $260M - $270M reaffirmed, representing 17-21% growth over 2021 For further details see: Amryt Pharma GAAP EPS of -$0.06, revenue of ...
Amryt Reports Q 3 2022 Financial and Operational Results 8. 2 % YoY revenue growth in Q 3 to $ 6 1 . 1 M - 12.5% on a const...
Amryt Supports Acromegaly Awareness Day 202 2 DUBLIN, Ireland, and Boston MA, October 31 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing...
The British Journal of Dermatology Publishes Results f rom Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 2 5 , 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical...
Amryt Supports Global EB Awareness Week 202 2 DUBLIN, Ireland, and Boston MA, Octo ber 2 4 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercia...
A mryt to Report Q 3 202 2 Results on November 3 , 2022 DUBLIN, Ireland, and Boston MA, October 19 , 202 2 , Amryt (Nasdaq: AMYT ) a global, commercial-stage...
A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's ( NASDAQ: AMYT ) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much gr...
COMP adopts positive opinion on O rphan D isease D esignation for Mycapssa® for the treatment of Acromegaly DUBLIN, Ireland, and Boston MA, October 18 , 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company d...
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin) DUBLIN, Ireland, and Boston MA, Oct o ber 1 7 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical com...
Amryt Supports FH Awareness Day – September 24, 202 2 DUBLIN, Ireland, and Boston MA, September 2 3 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializi...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...